Vera Labitzky

Dr. Vera Labitzky


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
VLVera Labitzky
Vera Labitzky
ABAnke Baranowsky
Anke Baranowsky
HMHanna Maar
Hanna Maar
SHSandra Hanika
Sandra Hanika
SSSarah Starzonek
Sarah Starzonek
TLTobias Lange
Tobias Lange
The majority of cancer-related deaths are due to hematogenous metastases, and the bone marrow (BM) represents one of the most frequent metastatic sites. To study BM metastasis formation in vivo, the most efficient approach is based on intracardiac injection of human tumor cells into immunodeficient mice. However, such a procedure circumvents the early steps of the metastatic cascade. Here we describe the development of xenograft mouse models (balb/c rag2-/- and severe combined immunodeficient (SCID)), in which BM metastases are spontaneously derived from subcutaneous (s.c.) primary tumors (PTs). As verified by histology, the described methodology including ex vivo bioluminescence imaging (BLI) even enabled the detection of micrometastases in the BM. Furthermore, we established sublines from xenograft primary tumors (PTs) and corresponding BM (BM) metastases using LAN-1 neuroblastoma xenografts as a first example. In vitro “metastasis” assays (viability, proliferation, transmigration, invasion, colony formation) partially indicated pro-metastatic features of the LAN-1-BM compared to the LAN-1-PT subline. Unexpectedly, after s.c. re-injection into mice, LAN-1-BM xenografts developed spontaneous BM metastases less frequently than LAN-1-PT xenografts. This study provides a novel methodologic approach for modelling the spontaneous metastatic cascade of human BM metastasis formation in mice. Moreover, our data indicate that putative bone-metastatic features get rapidly lost upon routine cell culture.

10 February 2015 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LOLeticia Oliveira-Ferrer
Leticia Oliveira-Ferrer
MKM. Kürschner
M. Kürschner
VLVera Labitzky
Vera Labitzky
DWD. Wicklein
D. Wicklein
VMV. Müller
V. Müller
CSC. Schröder
C. Schröder

19 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
FPFabian Bernhard Pallasch
Fabian Bernhard Pallasch
VLVera Labitzky
Vera Labitzky
MKMalte Kriegs
Malte Kriegs
DGDennis Gatzemeier
Dennis Gatzemeier
TMThomas Mair
Thomas Mair
Schumacher UdoSchumacher Udo
Schumacher Udo
Background: Remarkable differences exist in the outcome of systemic cancer therapies. Lymphomas and leukemias generally respond well to systemic chemotherapies, while solid cancers often fail. We engineered different human cancer cells lines to uniformly express a modified herpes simplex virus thymidine kinase TK.007 as a suicide gene when ganciclovir (GCV) is applied, thus in theory achieving a similar response in all cell lines. Methods: Fifteen different cell lines were engineered to express the TK.007 gene. XTT-cell proliferation assays were performed and the IC50-values were calculated. Functional kinome profiling, mRNA sequencing, and bottom-up proteomics analysis with Ingenuity pathway analysis were performed. Results: GCV potency varied among cell lines, with lymphoma and leukemia cells showing higher susceptibility than solid cancer cells. Functional kinome profiling implies a contribution of the SRC family kinases and decreased overall kinase activity. mRNA sequencing highlighted alterations in the MAPK pathways and bottom-up proteomics showed differences in apoptotic and epithelial junction signaling proteins. Conclusions: The histogenetic origin of cells influenced the susceptibility of human malignant cells towards cytotoxic agents with leukemias and lymphomas being more sensitive than solid cancer cells.